Periodic Reporting for period 1 - SpheroPredict (A 3D advanced test for prediction of drug response in secondary liver cancer)
Berichtszeitraum: 2017-01-01 bis 2017-04-30
SpheroPredict addresses this problem improving survival and quality of life in cancer patients. It is based on the spheroid model, which is 3D cell cultures from patients tumor samples that perfectly reproduce its response to chemotherapy drugs.
SPHEROPREDICT is an important issue for society regarding two pillars:
- Economical: The European economic impact imposed by cancer is estimated to be € 51 billion spent in healthcare and € 42.6 billion in productivity loss due to early death.
- Social: Secondary cancer is one of the leading causes of death worldwide and cancer is expected to lead to death over 11.5 million people by 2030 globally.
Objectives of the present feasibility study:
- Design a protocol of a large interventional study.
- Define a commercial strategy to reach our sales objectives.
- Built up the Work Plan. Define the sales plan and projections for the 5 years following the execution of Phase 2 project.
- Calculate the funding requirements for the execution of this project.
From our market study we are a expecting a big demand for SpheroPredict and we found that the potential available market is very broad. We have set our sales plan and projections for the 5 years following the execution of Phase 2 project. We calculated the funding requirements that SpheroPredict project needs to reach the objectives and get to TRL 9. We also assessed the infrastructure investment we need to scale up the production capacity.